- Diurnal Group, the speciality pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, has appointed Richard Bungay as chief financial officer, effective 16 January.

Bungay succeeds Ian Ardill who has given notice of his resignation as the company's CFO in order to pursue other business opportunities. Ardill will leave Diurnal on 13 January and will be available to support an orderly handover.

At 9:30am: [LON:DNL] Diurnal Group Plc share price was 0p at 106.5p

Story provided by